tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

AQST Stock Latest News

Buy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
RatingsBuy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
24d ago
AQST
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success
PremiumRatings
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success
25d ago
AQST
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating
PremiumRatings
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating
26d ago
AQST
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA
PremiumCompany Announcements
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA
26d ago
8K
AQST
Aquestive announces positive results from pediatric study for Anaphylm
PremiumThe Fly
Aquestive announces positive results from pediatric study for Anaphylm
26d ago
AQST
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position
PremiumRatingsOptimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position
2M ago
AQST
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges
2M ago
AQST
Aquestive Therapeutics Advances Product Pipeline and Market Access
Premium
Company Announcements
Aquestive Therapeutics Advances Product Pipeline and Market Access
2M ago
8K
AQST
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations
PremiumRatings
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations
2M ago
AQST
Aquestive Therapeutics price target lowered to $7 from $8 at Raymond James
PremiumThe Fly
Aquestive Therapeutics price target lowered to $7 from $8 at Raymond James
2M ago
AQST
Aquestive Therapeutics price target lowered to $8 from $10 at Lake Street
PremiumThe Fly
Aquestive Therapeutics price target lowered to $8 from $10 at Lake Street
2M ago
AQST
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners
PremiumThe Fly
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners
2M ago
AQST
Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress
PremiumCompany AnnouncementsAquestive Therapeutics Reports 2024 Financial Results and Strategic Progress
2M ago
AQST
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating
Premium
Ratings
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating
2M ago
AQST
Aquestive Therapeutics Initiates Anaphylm NDA Filing Process
Premium
Company Announcements
Aquestive Therapeutics Initiates Anaphylm NDA Filing Process
2M ago
8K
AQST
Aquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97M
PremiumThe Fly
Aquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97M
2M ago
AQST
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c)
PremiumThe Fly
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c)
2M ago
AQST
Options Volatility and Implied Earnings Moves Today, March 05, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 05, 2025
2M ago
FL
ZS
Options Volatility and Implied Earnings Moves This Week, March 03 – March 06, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, March 03 – March 06, 2025
2M ago
M
SE
Aquestive Therapeutics, Inc. (AQST) Q4 Earnings Cheat Sheet
PremiumPre-EarningsAquestive Therapeutics, Inc. (AQST) Q4 Earnings Cheat Sheet
2M ago
AQST
Aquestive Therapeutics to present new findings at AAAAI meeting
Premium
The Fly
Aquestive Therapeutics to present new findings at AAAAI meeting
2M ago
AQST
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress
Premium
Company Announcements
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress
3M ago
8K
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >